Therapeutic antibodies for human diseases at the dawn of the twenty-first century

@article{Brekke2003TherapeuticAF,
  title={Therapeutic antibodies for human diseases at the dawn of the twenty-first century},
  author={Ole Henrik Brekke and Inger Sandlie},
  journal={Nature Reviews Drug Discovery},
  year={2003},
  volume={2},
  pages={52-62}
}
Antibodies are highly specific, naturally evolved molecules that recognize and eliminate pathogenic and disease antigens. The past 30 years of antibody research have hinted at the promise of new versatile therapeutic agents to fight cancer, autoimmune diseases and infection. Technology development and the testing of new generations of antibody reagents have altered our view of how they might be used for prophylactic and therapeutic purposes. The therapeutic antibodies of today are genetically… Expand

Figures, Tables, and Topics from this paper

Recombinant polyclonal antibodies: the next generation of antibody therapeutics?
  • J. Haurum
  • Biology, Medicine
  • Drug discovery today
  • 2006
TLDR
Recombinant polyclonal antibodies, the third generation of antibody therapeutics, have the ability to tackle complex and highly mutagenic targets, and will undoubtedly offer a promising commercial future. Expand
The state of antibody therapy.
TLDR
This review provides a summary of the current state of antibody therapy, highlights and discusses recent developments in the field of antibody-based therapeutics production, combination therapy and shows the status of some of the agents that are in clinical trial. Expand
Technological Evolution in the Development of Therapeutic Antibodies.
TLDR
In recent years a new group of antibody based molecules has been developed to replace monoclonal antibodies, given their ability to overcome some of the limitations of the latter. Expand
Antibodies for Human Diseases
TLDR
This chapter will highlight the recent technological advances in monoclonal antibody (mAb) development that have caused significant investment and interest in the pharmaceutical and biotech industry. Expand
Antibody engineering for therapeutics.
  • L. Presta
  • Medicine, Biology
  • Current opinion in structural biology
  • 2003
TLDR
A potential new type of effector function for antibodies, that is, the generation of reactive oxygen species that may effect inflammation or bacterial killing, has been elucidated. Expand
The use of antibodies in the treatment of infectious diseases.
There is a long history of the use of antibodies in the treatment and prophylaxis of infectious diseases, because these molecules play a critical role in directing the effector mechanisms of theExpand
Advances in antibody engineering for rheumatic diseases
TLDR
The advancement of technologies for antibody production and engineering culminated in the production of fully human antibodies as well as antibody derivatives, which have an important role in the treatment of rheumatic diseases. Expand
Future prospects of monoclonal antibodies as magic bullets in immunotherapy.
TLDR
The large size and the long half-life of full-length antibody make them an inappropriate tool for radioimmunotherapy, therefore, scientists produced some antibody fragments including scFv, Diabody and Nanobodies (sdAbs) which have smaller size besides maintaining the binding activity of the full- length molecule. Expand
Recombinant Antibodies as Therapeutic Agents
TLDR
The present review focuses on the structural and functional characteristics of mAbs and their fragments, and also provides a walk through the most important methods used in antibody selection. Expand
Development of recombinant human polyclonal antibodies for the treatment of complex human diseases
TLDR
The authors believe that this new class of therapeutic antibodies will be advantageous in the treatment of complex human diseases, such as cancer and infection, as it allows the combination of several treatment modalities in one drug. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 86 REFERENCES
Engineering Antibodies for Targeted Cancer Therapy
The last few years have seen a revolution in molecular biology which has allowed greater understanding of the mechanisms of oncogenesis. Unfortunately this greater understanding has not yet led toExpand
The development of monoclonal antibodies for the therapy of cancer.
TLDR
This review discusses Mab-based strategies for the treatment of cancer and compares native, fragmented, recombinant and chimeric antibodies, bispecific antibodies, immunoconjugates, and immunoliposomes. Expand
Signaling antibodies in cancer therapy.
TLDR
Clinical results now confirm that these new reagents, when directed at the appropriate tumor markers (e.g. CD20 or Her-2), can control disease without untoward side effects. Expand
Human immune response to monoclonal antibodies.
  • M. Khazaeli, R. Conry, A. Lobuglio
  • Biology, Medicine
  • Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy
  • 1994
TLDR
This review article discusses what is known regarding human immune response to monoclonal antibodies and their clinical consequences. Expand
Production of functional chimaeric mouse/human antibody
The availability of monoclonal antibodies has revived interest in immunotherapy. The ability to influence an individual's immune state by administering immunoglobulin of the appropriate specificityExpand
Formatting antibody fragments to mediate specific therapeutic functions.
TLDR
Fab fragments (the fragment comprising one antigen-binding arm of the Y-shaped IgG molecule) can be formatted to mediate most mechanisms and have the advantage that valency and half-life can be controlled to simplify the drug and address only the mechanism required. Expand
PEGylated antibodies and antibody fragments for improved therapy: a review.
  • A. P. Chapman
  • Chemistry, Medicine
  • Advanced drug delivery reviews
  • 2002
TLDR
Previously reported experience with PEGylated antibodies and antibody fragments are described, and where these types of molecules may find clinical usefulness in the future. Expand
Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin.
TLDR
Analysis of three different commercial TIG preparations indicated that the majority of anti-TT antibodies is directed against epitopes expressed by the A fragment, the L chain of TT. Expand
IgA antibodies for cancer therapy.
TLDR
This work has shown that neutrophils--the most populous cytotoxic cells in humans--were more effectively recruited by human IgA than by IgG antibodies, and may have the additional advantages of forming natural dimers with improved signaling capacity on tumor cells, and being actively transported into mucosal secretions with the potential for improved targeting of certain carcinomas from the luminal surface. Expand
Bispecific antibodies targeting cancer cells.
TLDR
Results from clinical trials have been less promising so far and have revealed clear limitations of these molecules, such as short plasma half-lives compared with conventional antibodies, but the rationale for the generation of novel recombinant molecules is described. Expand
...
1
2
3
4
5
...